Treatment Patterns and Persistence Among Patients Newly Diagnosed With Migraine in South Korea: A Retrospective Analysis of Health Claims Data
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Migraine is one of the most common chronic neurological diseases worldwide. Although diverse treatment regimens have been recommended, there is insufficient evidence for which treatment patterns to apply in routine clinical settings. Methods We used nationwide claims data from South Korea for 2015–2021 to identify incident migraine patients with at least one prescription for migraine. Patients were categorized according to their initial treatment classes and followed up from the date of treatment initiation. Treatment regimens included prophylactic treatments (antidepressants, anticonvulsants, beta blockers, calcium-channel blockers, and renin-angiotensin-aldosterone system [RAAS] inhibitors) and acute treatments (acetaminophen, antiemetics, aspirin, ergotamine, nonsteroidal anti-inflammatory drugs [NSAIDs], opioids, and triptans). The treatment patterns of migraine were evaluated until the end of the study period, including the secular trends, prevalence, persistence, and changes in migraine treatment. Results Among the 761,350 included patients who received migraine treatment, the most frequently prescribed acute treatment was an NSAID (69.9%), followed by acetaminophen (50.0%). The most-prescribed prophylactic treatment was flunarizine (36.9%), followed by propranolol (24.4%). Among the patients, 54.8% received acute treatment, 13.5% received prophylactic treatment, and 31.6% received both treatment types. However, 65.7% of the patients discontinued their treatment within 3 months. The 3-month persistence rate was highest for triptans (25.2%) among the acute treatments and for RAAS inhibitors (62.0%) among the prophylactic treatments. Conclusions While the prevalence rates of medication use were found to align with current migraine guidelines, frequent switching and rapid discontinuation of drugs were observed in routine clinical settings.
Abstract
Background and Purpose Migraine is one of the most common chronic neurological diseases worldwide. Although diverse treatment regimens have been recommended, there is insufficient evidence for which treatment patterns to apply in routine clinical settings. Methods We used nationwide claims data from South Korea for 2015–2021 to identify incident migraine patients with at least one prescription for migraine. Patients were categorized according to their initial treatment classes and followed up from the date of treatment initiation. Treatment regimens included prophylactic treatments (antidepressants, anticonvulsants, beta blockers, calcium-channel blockers, and renin-angiotensin-aldosterone system [RAAS] inhibitors) and acute treatments (acetaminophen, antiemetics, aspirin, ergotamine, nonsteroidal anti-inflammatory drugs [NSAIDs], opioids, and triptans). The treatment patterns of migraine were evaluated until the end of the study period, including the secular trends, prevalence, persistence, and changes in migraine treatment. Results Among the 761,350 included patients who received migraine treatment, the most frequently prescribed acute treatment was an NSAID (69.9%), followed by acetaminophen (50.0%). The most-prescribed prophylactic treatment was flunarizine (36.9%), followed by propranolol (24.4%). Among the patients, 54.8% received acute treatment, 13.5% received prophylactic treatment, and 31.6% received both treatment types. However, 65.7% of the patients discontinued their treatment within 3 months. The 3-month persistence rate was highest for triptans (25.2%) among the acute treatments and for RAAS inhibitors (62.0%) among the prophylactic treatments. Conclusions While the prevalence rates of medication use were found to align with current migraine guidelines, frequent switching and rapid discontinuation of drugs were observed in routine clinical settings.
참고문헌 (31)
- Moon HS, "An update on migraine treatment", J Korean Neurol Assoc, 38, pp.100~110 (2020)
- Ashina M, "Migraine", N Engl J Med, 383, pp.1866~1876 (2020)
- Safiri S, "Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019", Pain, 163, pp.e293~e309 (2022)
- Buse D, "Development and validation of the migraine interictal burden scale(MIBS) : a self-administered instrument for measuring the burden of migraine between attacks", Neurology, 68, pp.A89~ (2007)
- Bigal ME, "Migraine and cardiovascular disease : a population-based study", Neurology, 74, pp.628~635 (2010)
- Minen MT, "Migraine and its psychiatric comorbidities", J Neurol Neurosurg Psychiatry, 87, pp.741~749 (2016)
- Ailani J, "The American Headache Society consensus statement : update on integrating new migraine treatments into clinical practice", Headache, 61, pp.1021~1039 (2021)
- Ashina M, "Migraine : integrated approaches to clinical management and emerging treatments", Lancet, 397, pp.1505~1518 (2021)
- World Health Organization, "Atlas of headache disorders and resources in the world 2011" (2011), World Health Organization
- Steiner TJ, "Aids for management of common headache disorders in primary care", J Headache Pain, 8(Suppl 1), pp.S2~ (2007)
- Kępczyńska K, "Botulinum toxin—a current place in the treatment of chronic migraine and other primary headaches", Toxins(Basel), 14, pp.619~ (2022)
- Hershey AD, "CGRP—the next frontier for migraine", N Engl J Med, 377, pp.2190~2191 (2017)
- Lipton RB, "Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine", N Engl J Med, 381, pp.142~149 (2019)
- Wang SJ, "Migraine disability awareness campaign in Asia : migraine assessment for prophylaxis", Headache, 48, pp.1356~1365 (2008)
- Buse DC, "Opioid use and dependence among persons with migraine : results of the AMPP study", Headache, 52, pp.18~36 (2012)
- Kim L, "A guide for the utilization of Health Insurance Review and Assessment Service national patient samples", Epidemiol Health, 36, pp.e2014008~ (2014)
- Park JW, "Chronic daily headache in Korea : prevalence, clinical characteristics, medical consultation and management", J Clin Neurol, 10, pp.236~243 (2014)
- Korean Headache Society, "Treatment guideline of pharmacological preventive therapy for episodic migraine" (2019), Medical Publisher
- Lipton RB, "Stratified care vs step care strategies for migraine : the disability in strategies of care(DISC)study : a randomized trial", JAMA, 284, pp.2599~2605 (2000)
- Orlando V, "Treatment patterns and medication adherence among newly diagnosed patients with migraine : a drug utilisation study", BMJ Open, 10, pp.e038972~ (2020)
- Bonafede M, "Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine", Cephalalgia, 39, pp.1086~1098 (2019)
- Wang YF, "Treatment pattern and health care resource utilization for Taiwanese patients with migraine : a population-based study", Front Neurol, 14, pp.1222912~ (2023)
- Degenhardt L, "Global patterns of opioid use and dependence : harms to populations, interventions, and future action", Lancet, 394, pp.1560~1579 (2019)
- Kim BK, "Burden of migraine and unmet needs from the patients’ perspective : a survey across 11 specialized headache clinics in Korea", J Headache Pain, 22, pp.45~ (2021)
- Ha H, "Migraine headache prophylaxis", Am Fam Physician, 99, pp.17~24 (2019)
- Meyers JL, "Treatment patterns and characteristics of patients with migraine in Japan : a retrospective analysis of health insurance claims data", Cephalalgia, 39, pp.1518~1534 (2019)
- Silberstein SD, "Practice parameter : evidence-based guidelines for migraine headache(an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology", Neurology, 55, pp.754~762 (2000)
- Hepp Z, "Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine : a retrospective claims analysis", Cephalalgia, 37, pp.470~485 (2017)
- Sacco S, "European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update", J Headache Pain, 23, pp.67~ (2022)
- Lipton RB, "Acute treatment patterns in patients with migraine newly initiating a triptan", Cephalalgia, 40, pp.437~447 (2020)
- Kim KM, "Prevalence, disability, and management patterns of migraine in Korea : nationwide survey data from 2009 and 2018", J Clin Neurol, 17, pp.77~85 (2021)